Dipropylcyclopentylxanthine – (102146-07-6)

Dipropylcyclopentylxanthine (DPCPX) is a potent and selective antagonist for the adenosine A1 receptor, with high selectivity over other adenosine receptor subtypes.

It also acts as a phosphodiesterase inhibitor, particularly PDE4, and has been used in studies to understand the role of adenosine A1 receptors in functions such as breathing regulation and brain activity. It triggers apoptosis in Jurkat T cells through a receptor-independent mechanism, involving DNA fragmentation and cell cycle arrest.

DPCPX is classified as an investigational drug and has been used in clinical trials for conditions like cystic fibrosis. Its chemical structure includes a xanthine core with cyclopentyl and dipropyl substituents.

The above informationis displayed for information purpose only, and has not been reviewed by EON nor does EON attests or validates the accuracy nor does it constitutes a recommendation or validation.

Sources:

https://en.wikipedia.org/wiki/Dipropylcyclopentylxanthine
https://go.drugbank.com/drugs/DB12946
https://pubmed.ncbi.nlm.nih.gov/14555978/